Crescita Therapeutics Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported revenue was CAD 6.03 million compared to CAD 2.99 million a year ago. Net income was CAD 0.195 million compared to net loss of CAD 0.9 million a year ago. Basic earnings per share from continuing operations was CAD 0.01 compared to basic loss per share from continuing operations of CAD 0.04 a year ago. Diluted earnings per share from continuing operations was CAD 0.01 compared to diluted loss per share from continuing operations of CAD 0.04 a year ago.
For the nine months, revenue was CAD 17.5 million compared to CAD 9.21 million a year ago. Net loss was CAD 0.316 million compared to CAD 2.05 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.1 a year ago. Diluted loss per share from continuing operations was CAD 0.02 compared to CAD 0.1 a year ago.